The European Medicines Agencys (EMAs) Committee for Medicinal Products for Human Use (CHMP) has recommended for approval a biosimilar of insulin glargine and three formulations of ertugliflozin, for type 2 diabetes viz. ertugliflozin monotherapy (Steglatro), fixed-dose ertugliflozin and metformin (Segluromet) and fixed-dose ertugliflozin and sitagliptin (Steglujan). All are indicated for adults aged 18 years and older with type 2 diabetes as adjuncts to diet and exercise to improve glycemic control.